Arthritis News and Research

Latest Arthritis News and Research

Study advances understanding of chronic and progressive nature of gout if treated inadequately

Emeritus professor of medicine, Elisio Pascual, at the Miguel Hernández Univeristy in Elche and former head of the Rheumatology Unit at Alicante University Hospital has published a research paper presenting previously unknown data that contribute to our understanding of gout as a crystal deposition disease.

29 Dec 2015

Pacemaker Induced Transient Asynchrony could help slow down progression of heart failure

Johns Hopkins has demonstrated in animals that applying a pacemaker's mild electrical shocks to push the heart in and out of normal synchronized contraction for part of each day may be an effective way to slow down the progression of heart failure, a disorder that afflicts millions of Americans.

24 Dec 2015

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the production of uric acid in the body.

22 Dec 2015

New study examines single 'transformer' proteins involved in cancer

A new study led by scientists at The Scripps Research Institute and St. Jude Children's Research Hospital shows how a protein involved in cancer twists and morphs into different structures.

22 Dec 2015

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Research that leads to improved therapies for Alzheimer's disease (AD) patients is one goal of Boston University School of Medicine professor of pharmacology and neurology Benjamin Wolozin, MD, PhD. He was one of six researchers awarded a two-year, $500,000 award in Alzheimer's Disease Drug Discovery Research by the Edward N. & Della L. Thome Memorial Foundation.

22 Dec 2015

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today emphasizes the continued availability of Daraprim and cautions healthcare providers of proposed alternatives to Daraprim.

20 Dec 2015

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

15 Dec 2015

Human body clock study paves way for drug treatment of osteoarthritis

A University of Manchester biologist has for the first time established that the painful and debilitating symptoms endured by osteoarthritis sufferers are intrinsically linked to the human body clock.

15 Dec 2015

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies, for the treatment of cancer and severe autoimmune diseases, announces that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease.

14 Dec 2015

TSRI-led study shows how different drugs regulate protein linked to asthma, obesity and diabetes

A new study, led by scientists at The Scripps Research Institute, shows how different pharmaceutical drugs hit either the "on" or "off" switch of a signaling protein linked to asthma, obesity and type 2 diabetes.

11 Dec 2015

Scientists find effective antiviral mechanisms to inhibit chikungunya virus

Scientists looking at the antiviral mechanisms of two previously identified human monoclonal antibodies have found they potently inhibit chikungunya virus (CHIKV) at multiple stages of infection.

11 Dec 2015

Vagus nerve stimulation prevents hemorrhagic complications following surgery

Stimulating the vagus nerve is a potentially efficacious and safe way to stop the flow of blood and prevent hemorrhagic complications following surgery and other invasive procedures, according to a researcher in the Center for Bioelectronic Medicine at The Feinstein Institute for Medical Research.

11 Dec 2015

Cancer drug can neutralize toxic RNA that causes myotonic dystrophy

A group of researchers has shown for the first time in cells and in a mouse model that a drug used to treat cancer can neutralize the toxic RNA that causes the prolonged muscle contractions and other symptoms of myotonic dystrophy type 1, the most common form of adult-onset muscular dystrophy.

11 Dec 2015

Oxford University researchers find that a blood test could predict rheumatoid arthritis risk

Scientists have found a marker that can indicate your likelihood of suffering from rheumatoid arthritis (RA) even sixteen years before the condition takes effect. A team from the Kennedy Institute of Rheumatology at Oxford University found that a blood test that looks for antibodies that recognize the protein tenascin-C could reliably show those who will contract the condition.

10 Dec 2015

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

New study may help doctors to better treat children who cope with chronic pain

A new study describes the development of pediatric pain measures for a National Institutes of Health Initiative aimed at helping doctors better evaluate and therefore better treat children who cope with chronic pain. Based on face-to-face interviews with pediatric patients, the study better captured the young patient's perspective of living with chronic pain.

9 Dec 2015

X-rays not reliable for diagnosing hip osteoarthritis in majority of cases

In the majority of cases, hip x-rays are not reliable for diagnosing hip osteoarthritis (OA), and can delay the treatment of this debilitating disease.

9 Dec 2015

Economic and racial barriers impact treatment of moderate to severe psoriasis

In the first known study to examine the prevalence and treatment of psoriasis in older Americans, experts from the Perelman School of Medicine at the University of Pennsylvania have found that black patients receiving Medicare are less likely to receive biologic therapies -medications derived from human or animal cells or tissues - for the treatment of moderate to severe psoriasis than white patients.

9 Dec 2015

Arthritis News and Research

Latest Arthritis News and Research

Study advances understanding of chronic and progressive nature of gout if treated inadequately

Pacemaker Induced Transient Asynchrony could help slow down progression of heart failure

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

New study examines single 'transformer' proteins involved in cancer

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Human body clock study paves way for drug treatment of osteoarthritis

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

TSRI-led study shows how different drugs regulate protein linked to asthma, obesity and diabetes

Scientists find effective antiviral mechanisms to inhibit chikungunya virus

Vagus nerve stimulation prevents hemorrhagic complications following surgery

Cancer drug can neutralize toxic RNA that causes myotonic dystrophy

Oxford University researchers find that a blood test could predict rheumatoid arthritis risk

Lilly, Merck announce another immuno-oncology collaboration

New study may help doctors to better treat children who cope with chronic pain

X-rays not reliable for diagnosing hip osteoarthritis in majority of cases

Economic and racial barriers impact treatment of moderate to severe psoriasis

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Arthritis News and Research

Latest Arthritis News and Research

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in